Sign up to receive the latest announcements on Woke Pharmaceuticals....
Latest Announcements
24.11.25
Press Release
Shareholder Announcement - THE UNIVERSITY OF SYDNEY EXECUTES SITE AGREEMENT TO PROGRESS PHASE II CLINICAL TRIAL INTO ALCOHOL USE DISORDER
Read More14.04.25
Press Release
SHAREHOLDER ANNOUNCEMENT MACQUARIE UNIVERSITY MICRODEP TRIAL SET TO ENTER NEXT PHASE OF RESEARCH
Read More06.11.24
Press Release
WOKE PHARMACEUTICALS AND UWA FILE A PROVISIONAL PATENT FOR NEW, SIMPLIFIED LSD ANALOGUES
Read More20.09.24
Press Release
WOKE EXTENDS RESEARCH PARTNERSHIP WITH UNIVERSITY OF WESTERN AUSTRALIA FOLLOWING DISCOVERY OF 55 NEW LSD COMPOUNDS
Read More20.06.24
Press Release
MACQUARIE UNIVERSITY RECRUITS FIRST PATIENTS FOR AUSTRALIA’S LARGEST PSYCHEDELIC FOCUSED CLINICAL TRIAL
Read More27.03.24
Press Release
UPDATE ON AUSTRALIA’S LARGEST PSYCHEDELICS TRIAL FOCUSED ON TREATMENT RESISTENT DEPRESSION
Read More16.02.23
Press Release
Woke Enters Clinical Agreement with Curtin University to Evaluate WP002 Psilocybin for Chronic Pain
Read More20.12.22
Press Release
Woke and Curtin University Sign Letter of Intent for Phase II trial of WP002 Psilocybin in Chronic Pain
Read More19.12.22
Press Release
Woke Enters Clinical Agreement with QIMR Berghofer to Evaluate WP002 Psilocybin for Prolonged Grief
Read More12.12.22
Press Release
Woke and University of Sydney Sign Clinical Trial Agreement for Phase IIB trial of WP002 Psilocybin in Alcohol Use Disorder
Read More18.10.22
Press Release
Woke and University of Sydney Sign Term Sheet for Phase II trial of WP002 Psilocybin in Alcohol Use Disorder
Read More16.08.22
Press Release
Woke and Swinburne University Sign Memorandum of Understanding to Develop WP002 Psilocybin-assisted Psychotherapy Phase IIB trial in Treatment-Resistant Depression
Read More12.08.22
Press Release
Woke and QIMR Berghofer Sign Letter of Intent for Clinical Trial of WP002 Psilocybin in Prolonged Grief
Read More08.06.22
Press Release
Woke and University of Western Australia collaborate to discover LSD analogues
Read More04.05.22
Press Release
Woke Announces First Shipment of Natural Health Products from HAVN Life Sciences
Read More27.04.22
Press Release
Woke Enters Clinical Agreement with Macquarie University for WP001 Low-dose Psilocybin for Moderate Depression
Read More07.04.22
Press Release
Woke Signs Manufacturing Agreement with IDT Australia for Novel Psilocybin Formulations to Treat Depression
Read More03.03.22
Press Release
Woke Expands Partnership with Monash University to Develop Novel Psilocybin Formulation for Treatment- Resistant Depression
Read More16.02.22
Press Release
Woke Signs Letter of Intent with The University of Western Australia to Identify Novel LSD Analogues
Read More03.02.22
Press Release
Woke Imports Psilocybin from Purisys in the US for Formulation of Novel Dosage Forms
Read More02.02.22
Press Release
Woke Signs Letter of Intent with IDT Australia for Manufacture of Novel Psilocybin Dosage Forms
Read More17.12.21
Press Release
Woke’s Response to TGA Decision to Maintain the Current Schedule 9 Classification for Psilocybin
Read More15.11.21
Press Release
Woke Completes Oversubscribed $1.55m Seed Capital Raising to Develop Medicinal Psychedelics
Read More14.11.21
Press Release
Woke Purchases Synthetic Psilocybin from Purisys for Formulation of Novel Dosage Forms
Read More07.11.21
Press Release
Woke and HAVN Life Enter into Agreement to Distribute Natural Health Products in AU, NZ and China
Read More19.10.21
Press Release
Woke Collaborates with Monash University to Develop Novel Psilocybin Formulation for Moderate Depression
Read More